ホーム>>Signaling Pathways>> DNA Damage/DNA Repair>> IRE1>>APY29

APY29

カタログ番号GC17139

ATP 競合阻害剤である APY29 は、280 nM の IC50 で ATP 結合ポケットに結合することにより、IRE1α の自己リン酸化を阻害する IRE1α のアロステリック モジュレーターです。 APY29 は、隣接する RNase ドメイン IRE1α をアロステリックに活性化するリガンドとして機能します。

Products are for research use only. Not for human use. We do not sell to patients.

APY29 化学構造

Cas No.: 1216665-49-4

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$127.00
在庫あり
10mg
$97.00
在庫あり
25mg
$209.00
在庫あり
50mg
$333.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

APY29 is an inhibitor of IRE1α with IC50 value of 0.28μM [1].

IRE1α is a transmembrane protein in ER. It can be activated when unfolded proteins accumulate in ER. APY29 is found to interact with the ATP-binding site of wild-type IRE1α and activate the kinase activity of IRE1α even without upstream ER stress. APY29 acts as a slight activator and stabilizes IRE1α’s kinase domain in an alternative conformation. It is found to restore the ability of dephosphorylated IRE1α to cleave the substrate XBP1 up to about 60% of the levels of normal IRE1α. Furthermore, APY29 increases the oligomer/monomer ratio of IRE1α and finally displays a decrease of IRE1α trans-autophosphorylation [1].

References:
[1] Wang L, Perera BG, Hari SB, Bhhatarai B, Backes BJ, Seeliger MA, Schürer SC, Oakes SA, Papa FR, Maly DJ. Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors. Nat Chem Biol. 2012 Dec;8(12):982-9.

レビュー

Review for APY29

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for APY29

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.